EGFR and neoplasm: BAX69 abrogates MIF signaling and MIF-mediated secretion of cytokines (IL-1β, TNF-α, etc.)and inhibits proliferation of MIF overexpressing tumor cells, together with the antiproliferative effects of panitumumab (anti-EGFR mAb).